FY2025 Earnings Forecast for Immunic Issued By William Blair

Immunic, Inc. (NASDAQ:IMUX) – Investment analysts at William Blair issued their FY2025 earnings per share estimates for shares of Immunic in a report issued on Monday, March 24th. William Blair analyst M. Minter forecasts that the company will post earnings per share of ($0.89) for the year. William Blair has a “Outperform” rating on the stock. The consensus estimate for Immunic’s current full-year earnings is ($0.94) per share.

Several other analysts have also commented on IMUX. HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of Immunic in a research report on Friday, February 21st. D. Boral Capital reissued a “buy” rating and set a $17.00 target price on shares of Immunic in a research report on Wednesday, February 26th. Finally, StockNews.com lowered shares of Immunic from a “hold” rating to a “sell” rating in a report on Thursday, March 20th. One equities research analyst has rated the stock with a sell rating, seven have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $12.67.

Immunic Price Performance

Shares of NASDAQ IMUX opened at $1.25 on Wednesday. The business has a fifty day moving average price of $1.07 and a 200 day moving average price of $1.21. Immunic has a 1-year low of $0.92 and a 1-year high of $2.11. The stock has a market capitalization of $112.60 million, a P/E ratio of -1.02 and a beta of 1.89.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. Focus Partners Wealth grew its holdings in shares of Immunic by 1.1% during the fourth quarter. Focus Partners Wealth now owns 2,168,353 shares of the company’s stock valued at $2,168,000 after buying an additional 23,610 shares during the last quarter. 683 Capital Management LLC grew its stake in Immunic by 2.2% during the 4th quarter. 683 Capital Management LLC now owns 700,000 shares of the company’s stock valued at $700,000 after purchasing an additional 15,349 shares during the last quarter. Millennium Management LLC increased its holdings in shares of Immunic by 480.6% in the fourth quarter. Millennium Management LLC now owns 579,683 shares of the company’s stock valued at $580,000 after purchasing an additional 479,846 shares during the period. Renaissance Technologies LLC raised its stake in shares of Immunic by 45.6% in the fourth quarter. Renaissance Technologies LLC now owns 566,623 shares of the company’s stock worth $567,000 after purchasing an additional 177,542 shares during the last quarter. Finally, Bridgeway Capital Management LLC lifted its holdings in shares of Immunic by 11.5% during the fourth quarter. Bridgeway Capital Management LLC now owns 215,000 shares of the company’s stock worth $215,000 after purchasing an additional 22,200 shares during the period. Institutional investors and hedge funds own 51.82% of the company’s stock.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.